Company Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.
The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia.
It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis.
In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer.
It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1887 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 34,100 |
| CEO | Christopher Boerner |
Contact Details
Address: Route 206 & Province Line Road Princeton, New Jersey 08543 United States | |
| Phone | 609 252 4621 |
| Website | bms.com |
Stock Details
| Ticker Symbol | BMY |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000014272 |
| CUSIP Number | 110122108 |
| ISIN Number | US1101221083 |
| Employer ID | 22-0790350 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher S. Boerner Ph.D. | Chief Executive Officer and Chairman |
| David V. Elkins | Executive Vice President and Chief Financial Officer |
| Samit Hirawat M.D. | Executive Vice President, Chief Medical Officer and Head of Development |
| Karin Shanahan | Executive Vice President of Global Product Development and Supply |
| Greg Meyers | Executive Vice President and Chief Digital and Technology Officer |
| Kimberly M. Jablonski | Chief Compliance and Ethics Officer |
| Cari Gallman | Executive Vice President, General Counsel and Chief Policy Officer |
| Ahn Amanda Poole | Executive Vice President and Chief Human Resources Officer |
| Dr. Joseph J. Eiden Jr. | Head of Medical Affairs |
| Adam Lenkowsky | Executive Vice President and Chief Commercialization Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | 10-Q | Quarterly Report |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 25, 2025 | 8-K | Current Report |
| Jun 6, 2025 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 6, 2025 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 6, 2025 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| May 15, 2025 | 25-NSE | Filing |
| May 7, 2025 | 8-K | Current Report |
| Apr 25, 2025 | SCHEDULE 13G | Filing |
| Apr 24, 2025 | 10-Q | Quarterly Report |